{"brief_title": "Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy", "brief_summary": "The purpose of the study is to determine if the two drugs can help patients feel better while causing the tumor to become smaller or disappear; evaluate the safety of giving both pemetrexed and gemcitabine in patients with advanced breast cancer.", "condition": ["Breast Cancer", "Breast Neoplasms"], "intervention_type": ["Drug", "Drug", "Drug", "Drug"], "intervention_name": ["Pemetrexed", "Gemcitabine", "Gemcitabine", "Pemetrexed"], "description": ["500 mg/m2, intravenous (IV), every 14 days, until disease progression", "1500 mg/m2, intravenous (IV), every 14 days, until disease progression", "1000 mg/m2, intravenous (IV), on Days 1 and 8 of 21-day cycle, until disease progression", "500 mg/m2, intravenous (IV), every 21 days, until disease progression"], "arm_group_label": ["A", "A", "B", "B"], "other_name": ["LY231514, Alimta", "LY188011, Gemzar", "LY188011", "Gemzar", "LY231514", "Alimta"], "criteria": "Inclusion Criteria: - Must have received prior chemotherapy with Taxol (paclitaxel) or Taxotere (docetaxel). - Less than 3 different chemotherapy treatments for metastatic disease. - Prior treatment with hormonal and/or radiation therapy. - Must have disease that can be measured. - Must be able to take care of self needs for example personal hygiene Exclusion Criteria: - Must not be pregnant or breast-feeding. - Cancer that has spread to the brain. - Treatment with Gemcitabine or Pemetrexed - Unable to take folic acid or Vitamin B12 - Treatment for another cancer within the last 5 years", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Cancer of the Breast", "mesh_term": ["Breast Neoplasms", "Gemcitabine", "Pemetrexed", "Taxane"], "id": "NCT00063570"}